BioSpace News Archive

Drug Development

NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers

NantKwest, Inc. (Nasdaq: NK), a clinical-stage natural killer cell-based therapeutics company, today announced promising safety data generated from the first six patients in its QUILT-3.064 trial.

December 2, 2019
·
5 min read
Kane Biotech to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) announced today that management will present an update on the Company’s business at the first annual BioTuesdays Pre-JPM Virtual Conference on Tuesday, December 10, 2019 at 2:00 p.m. Eastern Time.

December 2, 2019
·
2 min read
Biotech Bay

XOMA Announces Commencement of Rights Offering

XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced the previously announced rights offering to raise gross proceeds of approximately $22 million (the “Rights Offering”)

December 2, 2019
·
4 min read
Deals

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock - Dec. 2, 2019

Arrowhead Pharmaceuticals Inc. announced its intention to offer and sell 4,000,000 shares of its common stock in an underwritten offering pursuant to its existing automatic shelf registration statement.

December 2, 2019
·
4 min read
Business

AGTC Announces Departure of Chief Medical Officer, Company on Track to Announce XLRP and ACHM Data in January 2020

Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare diseases, announced that Theresa Heah, M.D., Chief Medical Officer, has resigned from the company to pursue other opportunities.

December 2, 2019
·
5 min read
Drug Development

1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Cellectis announced that the first patient enrolled in the dose escalation Phase 1 clinical study for its UCART22 product candidate has been dosed at The University of Texas MD Anderson Cancer Center.

December 2, 2019
·
5 min read
Pharm Country

Piper Jaffray to Host 31st Annual Healthcare Conference

Piper Jaffray Companies, a leading investment bank and institutional securities firm, will host its 31st annual Healthcare Conference in New York on December 3-5, 2019.

December 2, 2019
·
3 min read
Deals

Kodiak Sciences Announces Proposed Offering of Common Stock

Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced that it has commenced an underwritten public offering of $250,000,000 of shares of its common stock.

December 2, 2019
·
4 min read
Mallinckrodt Moves Date and Time of Its Fireside Chat at Piper Jaffray Annual Healthcare Conference

Mallinckrodt plc, a global biopharmaceutical company, announced that the Company now will present at the Piper Jaffray Annual Healthcare Conference on Wednesday, Dec. 4, 2019 at 12:30 p.m. Eastern..

December 2, 2019
·
2 min read